Search Within

Lauren Ashley Kaplanis

Formats
  1. Meeting Abstract (4)
  2. Journal Article (3)
Groups
  1. Nursing (7)
  2. Department of Medicine (6)
  3. Solid Tumor Oncology Division (6)
  4. Thoracic Oncology (6)
  5. Clinical Pharmacy Specialists (5)
  6. Division of Subspecialty Medicine (4)

More Groups

People
  1. Alexander Drilon (6)
  2. Dazhi Liu (5)
  3. Christina Falcon (4)
  4. Guilherme Harada (4)
  5. Clare Wilhelm (3)
  6. Yonina Murciano-Goroff (3)

More People

Years
  1. 2025 (1)
  2. 2022 (4)
  3. 2020 (1)
  4. 2019 (1)
Publications
  1. Journal of Clinical Oncology (2)
  2. Annals of Oncology (1)
  3. Cancer Research (1)
  4. JTO Clinical and Research Reports (1)
  5. Journal of Thoracic Oncology (1)
  6. Oncology Nursing Forum (1)
Publishers
  1. American Society of Clinical Oncology (2)
  2. American Association for Cancer Research (1)
  3. Elsevier BV (1)
  4. Elsevier Inc. (1)
  5. Oncology Nursing Society (ONS) (1)
  6. Oxford University Press (1)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mucocutaneous adverse events in patients with cancer treated with the highly selective RET kinase inhibitor selpercatinib (LOXO-292)
    Journal Article

    Reingold, R. E.; Parisi, R.; Harada, G.; Moy, A. P.; Dranitsaris, G.; Francis, J. H.; Canestraro, J.; Lester, J. A.; Kaplanis, L. A.; Liu, D.; more...
    JTO Clinical and Research Reports (2025)

    Fulltext@MSK | Save
  • Switching inhibitor class overcomes crizotinib resistance in a MET fusion-positive NSCLC with a novel acquired MET G1090A mutation
    Meeting Abstract

    Murciano-Goroff, Y. R.; Kannan, S.; Chang, J. C.; Benayed, R.; Blokhin, I.; Rekhtman, N.; Sisk, A. E.; Gibson, J.; Judka, L.; Kaplanis, L.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy
    Meeting Abstract

    Kalchiem-Dekel, O.; Falcon, C. J.; Bestvina, C. M.; Liu, D.; Kaplanis, L. A.; Wilhelm, C.; Eichholz, J.; Harada, G.; Wirth, L. J.; Lee, R. P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Mechanisms of acquired resistance to TRK inhibitors
    Meeting Abstract

    Harada, G.; Choudhury, N. J.; Schram, A. M.; Rosen, E.; Murciano-Goroff, Y. R.; Falcon, C. J.; Wilhelm, C.; Kaplanis, L. A.; Liu, D.; Chang, J. C.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Brief Report: Chylothorax and chylous ascites during RET tyrosine kinase inhibitor therapy
    Journal Article

    Kalchiem-Dekel, O.; Falcon, C. J.; Bestvina, C. M.; Liu, D.; Kaplanis, L. A.; Wilhelm, C.; Eichholz, J.; Harada, G.; Wirth, L. J.; Digumarthy, S. R.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • Characterization of on-target adverse events caused by TRK inhibitor therapy
    Journal Article

    Liu, D.; Flory, J.; Lin, A.; Offin, M.; Falcon, C. J.; Murciano-Goroff, Y. R.; Rosen, E.; Guo, R.; Basu, E.; Li, B. T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Genomic testing in the emerging era of precision medicine: Lessons learned from studies in larotrectinib
    Meeting Abstract

    Montez, S.; Kaplanis, L.; Ezrre, S.; Norman-Brivet, T.; Qamoos, H.; Genevieve, K.
    Oncology Nursing Forum (2019)

    Fulltext@MSK | Save